<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306604</url>
  </required_header>
  <id_info>
    <org_study_id>BN04/2011</org_study_id>
    <nct_id>NCT01306604</nct_id>
  </id_info>
  <brief_title>Biomarker for Niemann Pick Type C Disease</brief_title>
  <acronym>BioNPC</acronym>
  <official_title>Biomarker for Niemann Pick Type C Disease an International, Multicenter, Epidemiological Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Niemann Pick Syndrome Type C is a lysosomal storage disorder, caused by a pathological
      overload of cells with unesterified cholesterol as a result of impaired lipid transport into
      the cell, has still the problem of the difficulties of a simple and reliable analysis for the
      primary diagnosis but also for the follow-up of the disease. Therefore the primary aim of our
      project called &quot;BioNPC&quot; is the development of a new plasma biomarker for the early and
      sensitive diagnosis of the disease. The secondary aim is the testing for clinical robustness,
      specificity and long-term stability of the biomarker.

      Within the scope of the study the investigators would like to collect in the next 12 months
      from about 80 patient's plasma and parallel a simple documentation of the clinical data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Niemann-Pick disease type C (NPC) is a lipid storage disease that can present in infants,
      children, or adults. Neonates can present with ascites and severe liver disease from
      infiltration of the liver and/or respiratory failure from infiltration of the lungs. Other
      infants, without liver or pulmonary disease, have hypotonia and developmental delay. The
      classic presentation occurs in mid-to-late childhood with the insidious onset of ataxia,
      vertical supranuclear gaze palsy (VSGP), and dementia. Dystonia and seizures are common.
      Dysarthria and dysphagia eventually become disabling, making oral feeding impossible; death
      usually occurs in the late second or third decade from aspiration pneumonia. Adults are more
      likely to present with dementia or psychiatric symptoms. The diagnosis of NPC is confirmed by
      biochemical testing that demonstrates impaired cholesterol esterification and positive
      fillipin staining in cultured fibroblasts. Biochemical testing for carrier status is
      unreliable. Most individuals with NPC have NPC1, caused by mutations in the NPC1 gene; fewer
      than 20 individuals have been diagnosed with NPC2, caused by mutations in the NPC2 gene.
      Molecular genetic testing of the NPC1 genes detects disease-causing mutations in
      approximately 94% of individuals with NPC. Such testing is available clinically.

      NPC is inherited in an autosomal recessive manner. Each sib of an affected individual has a
      25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance
      of being unaffected and not a carrier. The phenotype (i.e., age of onset and severity of
      symptoms) usually runs true in families. Carrier testing for at-risk relatives and prenatal
      testing for pregnancies at increased risk are possible when the two disease-causing mutations
      have been identified in the family. Since the only accepted and easily accessible lab test,
      Fillipin staining of skin fibroblasts, is invasive and has a rather low sensitivity and
      specificity and genetic sequencing is tome-consuming and expensive there is an urgent need
      for the improvement of diagnostic biomarkers. New methods, like mass-spectometry give a good
      chance to characterize in the blood (plasma) of affected patents specific metabolic
      alterations that allow to diagnose in the future the disease earlier, with a higher
      sensitivity and specificity. The development of new biochemical markers from the plasma of
      the affected patients is the goal of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of a new MS-based biomarker for the early and sensitive diagnosis of Niemann Pick Type C disease from plasma and saliva</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Testing for clinical robustness, specificity and long-term stability of the biomarker</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Niemann-Pick Disease</condition>
  <condition>Niemann-Pick Disease, Type C</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Patients from the first day of life with Niemann Pick Type C syndrome NPC1/NPC2 or profound suspicion for Niemann Pick Type C syndrome NPC1/NPC2 disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For the development of the new biomarkers using the technique of Mass-spectometry 20ml EDTA
      and a dry blood spot filter card. To proof the correct NPC nosis in those patients where up
      to the enrollment in the study no genetic testing has been done, sequencing of NPC1 and/or
      NPC2 will be done. The analyses are done in the Albrecht-Kossel-Institute for
      Neuroregeneration (AKos) Gehlsheimerstr.20, 18055 Rostock (Germany)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of Niemann Pick Type C syndrome NPC1/NPC2 or profound suspicion
        for Niemann Pick Type C syndrome NPC1/NPC2 disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent will be obtained from the patient or their parents before any
             study related procedures

          -  Patients from the first day of life

          -  The patient has a diagnosis of Niemann Pick Type C syndrome NPC1/NPC2 or profound
             suspicion for Niemann Pick Type C syndrome NPC1/NPC2 disease

        High-grade suspicion present, if one or more criteria are valid:

          -  Positive family anamnesis for NPC1/NPC2

          -  Splenomegaly without identifiable cause

          -  Hepatomegaly without identifiable cause

          -  Neurological symptoms without identifiable cause

          -  Psychiatric symptoms without identifiable cause

        Exclusion Criteria:

          -  No written informed consent will be obtained from the patient or their parents before
             any study related procedures

          -  No diagnosis of NPC1/NPC2 or no valid criteria for high-grade suspicion of NPC1/ NPC2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arndt Rolfs, MD</last_name>
    <phone>+49 381 494</phone>
    <phone_ext>9540</phone_ext>
    <email>arndt.rolfs@med.uni-rostock.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Zielke</last_name>
    <phone>+49 381 494</phone>
    <phone_ext>4739</phone_ext>
    <email>susanne.zielke@med.uni-rostock.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pediatric practice</name>
      <address>
        <city>Oran</city>
        <zip>31000</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdelmadjid Benmansour, MD</last_name>
      <email>benmansour_b@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Abdelmadjid Benmansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juan Fernandez Hospital, Department of Neurology</name>
      <address>
        <city>Buenos Aires</city>
        <zip>Cerviño 3356</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Politei, MD</last_name>
      <phone>+54 11 480 82600</phone>
      <email>jpolitei@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Politei, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Technology Assessment in Clinical Genetics Research Group</name>
      <address>
        <city>Porto Alegre -RS</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Vanessa Schwartz, Prof</last_name>
      <email>idadschwartz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ida Vanessa Schwartz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre-Servico de Genetica Medica</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Giugliani, MD</last_name>
      <phone>+55 51 3316</phone>
      <phone_ext>8011</phone_ext>
      <email>rgiugliani@hcpa.ufrgs.br</email>
    </contact>
    <investigator>
      <last_name>Roberto Giugliani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinics Hospital of Ribeirao Preto- University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Marques Lourenco, MD</last_name>
      <email>charlesgenetica@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Charles Marques Lourenco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Pediatric Hospital of Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radka Tincheva, MD</last_name>
      <phone>+359 889 811</phone>
      <phone_ext>976</phone_ext>
      <email>drrtincheva@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Radka Tincheva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hosoital Rigshospitalet, Endokrinologisk ward</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla Feldt Rasmussen, Prof MD</last_name>
      <phone>+45 35451023</phone>
      <email>ufeldt@rh.dk</email>
    </contact>
    <investigator>
      <last_name>Ulla Feldt Rasmussen, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albrecht-Kossel-Institute for Neuroregeneration (AKos) Centre for Mental Health Disease University of Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Rolfs, Prof.</last_name>
      <phone>+49 381 494</phone>
      <phone_ext>9540</phone_ext>
      <email>arndt.rolfs@med.uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Anne Katrin Giese, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aristotle University of Thessaloniki-Ippokration General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitrios Zafeiriou, MD</last_name>
      <email>jeff@med.auth.gr</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Zafeiriou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIRMAN, University of Mumbai</name>
      <address>
        <city>Mumbai</city>
        <zip>400705</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Jalan, MD</last_name>
      <email>jalananil@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Anil Jalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research center University of Welfare Science, Medical Genetics Department Sarem Women Hospital</name>
      <address>
        <city>Teheran</city>
        <zip>13969</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousef Shafeghati, MD</last_name>
      <phone>+98(21) 44 633</phone>
      <phone_ext>283</phone_ext>
      <email>y_shafeghati@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yousef Shafeghati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Child Neurology</name>
      <address>
        <city>Rome</city>
        <zip>00188</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Leuzzi, Prof.</last_name>
      <phone>+39644712282</phone>
      <phone_ext>272925</phone_ext>
      <email>vincenzo.leuzzi@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Mario Mastrangelo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Letizia Nunziata, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children´s Memorial Istitute Poland - Department of Metabolic Disease</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Tylki-Szymanska, Prof.</last_name>
      <phone>+48 228 15</phone>
      <phone_ext>74 90</phone_ext>
      <email>atylki@czd.waw.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Tylki-Szymanska, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dhahran Health Center - Saudi Aramco Medical Services Organization</name>
      <address>
        <city>Dhahran</city>
        <zip>31311</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nouriya Al-Sannaa, MD</last_name>
      <phone>+9663 877</phone>
      <phone_ext>8290</phone_ext>
      <email>nouriya.sannaa@aramco.com</email>
    </contact>
    <investigator>
      <last_name>Nouriya Abbas Al-Sannaa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mother and Child Health Institute of Serbia - Dr. Vukan Cupic</name>
      <address>
        <city>Novi Beograd</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrijan Sarajlija, MD</last_name>
      <email>adrijans2004@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adrijan Sarajlijan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Iran, Islamic Republic of</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
  </location_countries>
  <link>
    <url>http://centogene.com</url>
    <description>Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders. We now offer more than 2200 routine genetic and biochemical tests.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rostock</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Arndt Rolfs</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Genetic Diseases</keyword>
  <keyword>Lipidoses</keyword>
  <keyword>Lipid Metabolism</keyword>
  <keyword>Lysosomal Storage Diseases</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

